Argenx Se (ARGX) EBITDA Margin (2016 - 2026)
Argenx Se (ARGX) posted EBITDA Margin of 30.35% for Q1 2026, up 6.16% on a QoQ basis from 28.59% in Q4 2025, and up 1276.0% year-over-year from 2.21% in Q1 2025.
Argenx Se (ARGX) EBITDA Margin (2016 - 2026) Analysis & Trends
Argenx Se's EBITDA Margin history runs 11 years deep, the most recent figure standing at 30.35% for Q1 2026.
- Quarterly EBITDA Margin rose 1276.0% year-over-year to 30.35% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 28.09% (up 1991.0% YoY) and the FY2025 annual result came in at 25.38%, up 2638.0% from the prior year.
- EBITDA Margin was 30.35% for Q1 2026 at Argenx Se, up from 28.59% in the prior quarter.
- Across five years, EBITDA Margin topped out at 30.72% in Q3 2025 and bottomed at 1052.43% in Q1 2022.
- A 5-year average of 90.92% and a median of 23.46% in 2024 frame the typical range for EBITDA Margin.
- Peak annual rise in EBITDA Margin reached 2000000000 bps in 2022, while the deepest fall reached 15887 bps in 2022.
- Argenx Se's EBITDA Margin stood at 65.99% in 2022, then jumped by 44 bps to 37.03% in 2023, then jumped by 138 bps to 13.98% in 2024, then jumped by 104 bps to 28.59% in 2025, then increased by 6 bps to 30.35% in 2026.
- Business Quant data shows ARGX's EBITDA Margin at 30.35% in Q1 2026, 28.59% in Q4 2025, and 30.72% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 30.35% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 23.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.35% |
| Dec 31, 2025 | 28.59% |
| Sep 30, 2025 | 30.72% |
| Jun 30, 2025 | 21.20% |
| Mar 31, 2025 | 17.59% |
| Dec 31, 2024 | 13.98% |
| Sep 30, 2024 | 2.48% |
| Jun 30, 2024 | -9.52% |
| Mar 31, 2024 | -23.46% |
| Dec 31, 2023 | -37.03% |
| Sep 30, 2023 | -24.49% |
| Jun 30, 2023 | -37.91% |
| Mar 31, 2023 | -47.58% |
| Dec 31, 2022 | -65.99% |
| Sep 30, 2022 | -158.87% |
| Jun 30, 2022 | -233.24% |
| Mar 31, 2022 | -1,052.43% |
| Dec 31, 2021 | -887.37% |
| Sep 30, 2021 | 0.00% |
| Jun 30, 2021 | -20,624,445,517.56% |